-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Q5CsKZHQyD3ZICsvR9m81yylAPUeu2ZtPgEfQUZiv9jFZUD9PcR1oXWeITwmPG/P uqtCEz7+UGucVQUV1RLQfA== 0000892569-03-002865.txt : 20031222 0000892569-03-002865.hdr.sgml : 20031222 20031222152911 ACCESSION NUMBER: 0000892569-03-002865 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20031222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SPECTRUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000831547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930979187 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-110103 FILM NUMBER: 031067601 BUSINESS ADDRESS: STREET 1: 157 TECHNOLOGY DR CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 9497886700 MAIL ADDRESS: STREET 1: 157 TECHNOLOGY DR CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: NEOTHERAPEUTICS INC DATE OF NAME CHANGE: 19960819 FORMER COMPANY: FORMER CONFORMED NAME: AMERICUS FUNDING CORP DATE OF NAME CHANGE: 19920703 424B3 1 a95325e424b3.htm 42B3 Spectrum Pharmaceuticals, Inc.
 

     
    Filed Pursuant to Rule 424(B)(3)
    Registration Statement No. 333-110103
     
PROSPECTUS SUPPLEMENT NO. 1    
(TO PROSPECTUS DATED NOVEMBER 13, 2003)    

PROSPECTUS

UP TO 7,264,370 SHARES OF

SPECTRUM PHARMACEUTICALS, INC.

COMMON STOCK

     This prospectus supplement relates to the sale of up to 7,264,370 shares of our common stock by the selling stockholders named in this prospectus supplement and the prospectus dated November 13, 2003. This prospectus supplement should be read in conjunction with the prospectus which is to be delivered with this prospectus supplement.

     The information appearing in the table below, as of the date hereof, supplements the information in the table appearing under the heading “Selling Stockholders” in the prospectus, and, where the name of a selling stockholder identified in the table below also appears in the table in the prospectus, the information set forth in the table below regarding that selling stockholder supersedes the information in the prospectus. A selling stockholder named in the prospectus transferred to the entities listed in the table below the securities which are convertible or exercisable for the shares of our common stock listed in the table below.

                                         
    Shares of Common Stock           Shares of Common Stock
    Beneficially Owned           Beneficially Owned
    Before Offering   Number of Shares of   Following the Offering(2)
   
  Common Stock  
Name   Number   % of Class(1)   Offered Hereby   Number   % of Class
 
 
 
 
 
Shipman & Goodwin LLP Profit Sharing Plan Trust fbo James T. Betts (3)
     101,700       1.42 %     20,000       81,700       1.14 %
Trust u/a Helen M. Betts fbo James T. Betts et al. (4)
     26,500       *       14,000       12,500       *  

*   Represents less than 1%
 
(1)   For the purposes of calculating the percent of class beneficially owned by a selling stockholder, shares of common stock which may be issued to that selling stockholder within 60 days of December 5, 2003 are deemed to be outstanding.
 
(2)   Assumes the sale by the selling stockholders of all of the shares of common stock available for resale under the prospectus.
 
(3)   James T. Betts has investment and voting power over the shares beneficially owned by Shipman & Goodwin LLP Profit Sharing Plan Trust fbo James T. Betts.
 
(4)   James T. Betts has investment and voting power over the shares beneficially owned by Trust u/a Helen M. Betts fbo James T. Betts et al.

     INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE “RISK FACTORS” BEGINNING ON PAGE 1 OF THE PROSPECTUS.

     Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is December 11, 2003

-----END PRIVACY-ENHANCED MESSAGE-----